Composition for prevention and treatment of muscular diseases or for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract

Abstract

The present invention relates to a composition for preventing or treating a muscle disorder, which includes a Chrysanthemum extract or 3,5-dicaffeoylquinic acid as an active ingredient, and specifically, it may be used to reduce mRNA expression of atrogin-1 and MuRF1, which are main biomarkers involved in muscle protein degradation and increase mRNA expression of the mTOR protein, which is a main biomarker involved in muscle protein formation, and myogenin and MyoD, which are biomarkers related to muscle differentiation, thereby reducing muscle loss, and thus the Chrysanthemum extract or 3,5-dicaffeoylquinic acid can be used in prevention and treatment of a muscle disorder, or improvement in muscle function. In addition, the Chrysanthemum extract or 3,5-dicaffeoylquinic acid increases the activity of SIRT1 and PGC-1α, which are the main biomarkers involved in exercise performance, thereby excellently enhancing exercise performance. In addition, the present invention is a natural substance and may be safely used without a side effect, and therefore may be used as a medication, food or a cosmetic.

1 . A method of improving exercise performance, comprising:
 administering a pharmaceutically acceptable amount of a  Chrysanthemum  extract, or 3,5-dicaffeoylquinic acid represented by Formula 1 below or a pharmaceutically acceptable salt thereof into a subject:   
       
         
           
           
               
               
           
         
       
     
     
         2 . The method according to  claim 1 , wherein the improving exercise performance comprises preventing or treating any of one or more diseases selected from the group consisting of a degenerative disease, mitochondrial dysfunction, a decrease in endurance, a decrease in agility, lethargy, muscle disuse and depression. 
     
     
         3 . The method according to  claim 1 , wherein the administration increases oxidative metabolic function of mitochondria, increases SIRT1 and PGC-1α expression levels in muscle cells, promotes formation of muscle fibers, or increases PPARδ activity. 
     
     
         4 . The method according to  claim 1 , wherein the  Chrysanthemum  extract is a  Chrysanthemum morifolium  extract. 
     
     
         5 . The method according to  claim 1 , wherein the  Chrysanthemum  extract is obtained by extracting  Chrysanthemum  using water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent. 
     
     
         6 . The method according to  claim 1 , wherein the  Chrysanthemum  extract is obtained by extracting  Chrysanthemum  by subcritical fluid extraction, supercritical fluid extraction or ultra-high pressure extraction. 
     
     
         7 . The method according to  claim 1 , wherein the 3,5-dicaffeoylquinic acid is a compound isolated from a  Chrysanthemum  extract. 
     
     
         8 . The method according to  claim 1 , wherein the  Chrysanthemum  extract includes 3,5-dicaffeoylquinic acid represented by Formula 1 below: 
       
         
           
           
               
               
           
         
       
     
     
         9 . The method according to  claim 2 , wherein the administration increases oxidative metabolic function of mitochondria, increases SIRT1 and PGC-1α expression levels in muscle cells, promotes formation of muscle fibers, or increases PPARδ activity. 
     
     
         10 . The method according to  claim 2 , wherein the  Chrysanthemum  extract is a  Chrysanthemum morifolium  extract. 
     
     
         11 . The method according to  claim 2 , wherein the  Chrysanthemum  extract is obtained by extracting  Chrysanthemum  using water, an organic solvent having 1 to 6 carbon atoms or a mixture thereof as a solvent. 
     
     
         12 . The method according to  claim 2 , wherein the  Chrysanthemum  extract is obtained by extracting  Chrysanthemum  by subcritical fluid extraction, supercritical fluid extraction or ultra-high pressure extraction. 
     
     
         13 . The method according to  claim 2 , wherein the 3,5-dicaffeoylquinic acid is a compound isolated from a  Chrysanthemum  extract. 
     
     
         14 . The method according to  claim 2 , wherein the  Chrysanthemum  extract includes 3,5-dicaffeoylquinic acid represented by Formula 1 below: